Recent clinical trials have yielded mixed results with significant implications. Altimmune's phase 2b trial of pemvidutide, a GLP-1/glucagon dual receptor agonist for metabolic dysfunction-associated steatohepatitis (MASH), demonstrated achievement of one primary endpoint but missed another, triggering a steep stock decline. This highlights the ongoing challenges in developing effective therapies for serious fatty liver diseases. Parallel advancements include ongoing phase 3 studies for autoimmune and cardiovascular agents, underscoring the dynamic clinical development landscape.